CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th
VANCOUVER, Wash., Sept. 15, 2026 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic colorectal cancer (mCRC) and triple-negative breast cancer (TNBC), today announced…
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
